Aquestive Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. We'll be making a start. Welcome to the 2026 Jefferies Global Healthcare Conference. It is my pleasure to now introduce Dan Barber, CEO of Aquestive Therapeutics. Just as a reminder, this is a 20-minute presentation with time for Q&A at the end, so please leave any questions for the end.
Thank you. Thank you, and good morning, everyone.
You guys can hear me? You can hear me okay? All right. First, thank you to Jefferies for inviting us. Thank you to all of you for coming this morning. This is actually our first Jefferies presentation, so really excited for the conversation today. Of course, this is our safe harbor language. The PowerPoint is available on our website. You can download it at your leisure and read this in its entirety if you so choose. For those of you who may not be familiar with Aquestive, we've actually been around for around 20 years. We've been public. We're traded on NASDAQ for the last eight years, and we have six FDA approvals over the course of that time. Beyond the FDA approvals, we also have approvals around the world, and I'll talk about those a little later.
We do have two technologies. Our core technology is PharmFilm, which is an oral thin film technology. We are the world leader in that technology, and world leader is either approved products, amount of doses put into commerce, which is 2.5 million, or different markets that we are in, which is across the globe. In addition, we have a patent portfolio of over 100 patents, and we have a pipeline that we believe has the ability to have $1 billion or more in annual revenue as we go forward. I'm very lucky. I get to work with a fantastic team. With me today is Ernie Toth, our CFO. But I'll point out two other individuals that are important to our story. You'll see Dr. Matt Greenhawt on here, our Chief Medical Officer. He is one of the most published allergists in the planet.
We also have Shari Korchinski, our Chief Commercial Officer, who previously ran the EpiPen brand at Mylan. As we go farther into our story, that will be an important point. I mentioned PharmFilm before, and I said we have two technologies. PharmFilm is the technology that has historically been with the company for the last 20 years, but we also have a newer technology, the technology where we put our resources and our effort as we go forward, and we call that AdrenaVerse. AdrenaVerse is simply epinephrine with a variety of prodrugs attached, so a library of prodrug epinephrine products. What makes that interesting, if you think about epinephrine, it is a vasoconstrictor, so it's hard to absorb, and it also has a half-life of five minutes, so it's gone very quickly.
The use for epinephrine to date has been rescue medication, cardiac arrest in the hospital, or in dentistry to stop bleeding. With our portfolio, though, we believe we can expand that pipeline to be in areas beyond rescue. If you think of pulmonology, gastro, dermatology, we think there is a variety of places that we can put our AdrenaVerse technology to use. As I said before, our technology that we have had to date is PharmFilm. What you are looking at on this page are our approved products that are around the world. We make Emylif for Zambon in Europe. We make Suboxone for Indivior, which is now Suprenza in the U.S. and Australia. We have Sympazan with Cosette in the U.S., and Ondif with Hypera in Brazil. We just recently announced a relationship with Eton Pharmaceuticals for Libervant in the U.S.
If you look at our pipeline, I mentioned Libervant, that will be approved in the U.S. in the first quarter. It is actually tentatively approved already. It has an orphan drug exclusivity that it is waiting to expire, and that will come to the market. As I mentioned before, we have out-licensed that. If you put Libervant aside, you will notice the rest of our pipeline is AdrenaVerse. Anaphylm, our lead asset, dibutepinephrine sublingual film, if approved by the FDA, will be indicated for the treatment of severe allergic reactions, including anaphylaxis. We also have AQST-108, which is a topical gel version of epinephrine, a different prodrug of epinephrine, which will be indicated for atopic dermatitis in phase I at this point. I will actually spend the rest of my comments today on our lead asset, Anaphylm.
Just as a little background before we get into the story of Anaphylm, this is a product that we have filed with the FDA. We actually originally filed our NDA in March of 2025. We did receive a CRL, a complete response letter, in January of this year. That complete response letter was only for packaging and administration instructions. We quickly redid the deficiencies on the product. We have resubmitted it to the FDA, and we have an action date of March 16, of next year. In addition, thanks to the good work of Ernie, we have the balance sheet to launch Anaphylm in the U.S. on our own. At the end of the last quarter, we had $90 million of cash.
We had $75 million that has been committed by RTW upon approval for sales launch, and we also have access to $20 million under our Oaktree vehicle. Altogether, that is just under $200 million that will be available to us when we go to launch in the spring. Let us dig deeper into the story of Anaphylm. If you are familiar with the anaphylaxis space, if you are familiar with how it is treated today, almost everyone on the planet is familiar with EpiPen. It is like Kleenex, it is like Xerox. Kleenex, Xerox, it is the names that you know. When you look at the auto-injector, the EpiPen auto-injector, there is a variety of problems that are obvious. One, it is a needle, so people naturally do not want to use a needle. Two, it is bulky to carry.
Three, from a durability perspective, when you go through your daily life, it's not very durable. So, in terms of documenting in the literature whether there's an issue or not in this space, there's a host of documents and allergist-driven data around the need for something better. That's where our product comes into play. We are non-device, as I talked to you before. You can actually see on the back of my phone how you can carry our product. The durability of the product is superior to the auto-injector. It doesn't freeze. It can go to temperatures above 150 degrees Fahrenheit. It is water-resistant. You can fold it, you can put it in your wallet, you can take it with you wherever you go. It is needle-free, it is nozzle-free. Most importantly, beyond the ease of carry and use, we actually have a really compelling clinical package.
Now, before I get into the clinical package, if you want to look at the carry preference, let's talk about the carry preference versus a nasal spray, since a nasal spray did recently come to the market in the U.S. We asked 53 people, we had them sit down, we gave them the film, and we gave them a nasal spray, and we asked them which they would prefer. Of the 53 people, as you can see on the chart, 51 of them said the film, one said the nasal spray, and one said, "I don't care." So we feel from a preference standpoint, we have a product that is compelling. Let's talk a little bit more about the science. For those of you who know this space well, you know that time is crucial in this space.
As your body goes through a severe allergic reaction, you have mast cell degranulation, histamine release into the blood, and you're starting to have symptoms. You are starting to have difficulty breathing, you're starting to panic, your tongue is swelling up, a whole lot of bad things are starting to happen. If you wait 30 minutes to treat, you have three times the risk of a bad outcome. Bad outcome can be hospitalization, or it can be worse. So time matters when it comes to anaphylaxis. That's where we shine. If you consider time as absorption, our product has the fastest absorption profile of the products and the platforms that are available for anaphylaxis. So what you're looking at here is our time to peak absorption. So ours is 12 minutes, as you can see, and even the auto-injector takes 20 minutes.
But if Dr. Matt Greenhawt, our Chief Medical Officer, were here, he would say, "That's great. It's great that you have absorption so quickly, but what really matters is when the symptoms start going away." Especially if you are a patient, the only thing you care about is make it stop. So from our perspective, that's where pharmacodynamic data comes in. One of the quickest ways a physician can tell if a severe allergic reaction is abating is blood pressure. Is blood pressure coming back up? What you're looking at on this chart is how our product changes baseline blood pressure, systolic and diastolic, from the time of dosing. What you'll see, and on the right-hand side, you see the green line at the top, that's our film, and you can see the dramatic change from baseline.
The next line down, I believe that is a blue color, is actually the EpiPen. We have a higher and more extensive change in blood pressure when compared to the auto-injector. Importantly, you will see on the diastolic blood pressure, for the auto-injector, diastolic actually goes down. Or excuse me, the EpiPen actually goes down for diastolic. That is not good. You want both systolic and diastolic going up so that your mean arterial pressure is getting to the right place. With our product, we impact both systolic and diastolic, and we see that as a distinct advantage from a pharmacodynamic impact. On the right-hand side, you will also see the change in heart rate. It is important to note that while we do have a change in heart rate, it is not extreme, which is good from a physician perspective.
As part of our complete response letter from the FDA, one of the things the FDA was concerned about is people are people. They do not always follow their instructions. Someone or someones are going to put the film on top of their tongue instead of sublingually. The FDA asked us to look and see what would happen, what is going on in the body when you do put it on top of the tongue. The pharmacokinetic data is lower, so we do have a drop in PK. It still is above 100 picograms per milliliter, which is what the therapeutic window would be. However, our pharmacodynamic data, as you see on this slide, is actually still very strong. Our change from baseline, on the right-hand side for systolic, is actually still in line with what you would see for the auto-injector.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
